LEGEND
A Phase 1/2 Study of EG-70 as an Intravesical Administration to Patients With BCG Unresponsive Non-Muscle Invasive Bladder Cancer (NMIBC) and High-Risk NMIBC Patients Who Are BCG Naïve or Received Incomplete BCG Treatment Nature and Objective:This Phase 1/2 study evaluates the safety, tolerability, and preliminary efficacy of EG-70, a novel non-viral gene therapy, administered intravesically […]